AstraZeneca axes NSCLC trial after bispecific deemed unlikely to best Keytruda

Phase 3negativebispecificKeytrudaNegative

AI Analysis

Summary

AstraZeneca discontinued a Phase III NSCLC trial with its bispecific candidate after determining it was unlikely to outperform Merck's Keytruda, though the company announced positive data with other oncology assets.

Clinical Trial Data

Phase

Phase III

Primary Endpoint

Not Met

Outcome Details

Phase III trial discontinued; bispecific deemed unlikely to outperform Keytruda

Importance:6/10

Sentiment:

-0.80

oncologyNSCLCtrial discontinuationbispecific antibodycompetitive failure

Related Companies

$AZN

Read the original article

Published by Clinical Trials Arena on August 17, 2026 10:34 AM

Read Original